426 related articles for article (PubMed ID: 23246628)
21. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
Zhang P; Han X; Tan W; Chen D; Sun Q
Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
[TBL] [Abstract][Full Text] [Related]
22. Multiomic Profiling Identified EGF Receptor Signaling as a Potential Inhibitor of Type I Interferon Response in Models of Oncolytic Therapy by Vesicular Stomatitis Virus.
Nikitina AS; Lipatova AV; Goncharov AO; Kliuchnikova AA; Pyatnitskiy MA; Kuznetsova KG; Hamad A; Vorobyev PO; Alekseeva ON; Mahmoud M; Shakiba Y; Anufrieva KS; Arapidi GP; Ivanov MV; Tarasova IA; Gorshkov MV; Chumakov PM; Moshkovskii SA
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563635
[TBL] [Abstract][Full Text] [Related]
23. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.
Shulak L; Beljanski V; Chiang C; Dutta SM; Van Grevenynghe J; Belgnaoui SM; Nguyên TL; Di Lenardo T; Semmes OJ; Lin R; Hiscott J
J Virol; 2014 Mar; 88(5):2927-40. PubMed ID: 24371063
[TBL] [Abstract][Full Text] [Related]
25. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
[TBL] [Abstract][Full Text] [Related]
26. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH
J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853
[TBL] [Abstract][Full Text] [Related]
27. Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.
Guayasamin RC; Reynolds TD; Wei X; Fujiwara M; Robek MD
J Virol; 2014 Sep; 88(18):10909-17. PubMed ID: 25008938
[TBL] [Abstract][Full Text] [Related]
28. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
Bishnoi S; Tiwari R; Gupta S; Byrareddy SN; Nayak D
Viruses; 2018 Feb; 10(2):. PubMed ID: 29473868
[TBL] [Abstract][Full Text] [Related]
29. JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models.
Patel MR; Dash A; Jacobson BA; Ji Y; Baumann D; Ismail K; Kratzke RA
Cancer Gene Ther; 2019 Nov; 26(11-12):411-418. PubMed ID: 30622322
[TBL] [Abstract][Full Text] [Related]
30. Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model.
Tang S; Shi L; Luker BT; Mickler C; Suresh B; Lesinski GB; Fan D; Liu Y; Luo M
Virol J; 2022 Feb; 19(1):32. PubMed ID: 35197076
[TBL] [Abstract][Full Text] [Related]
31. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
[TBL] [Abstract][Full Text] [Related]
32. PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses.
Sobol PT; Hummel JL; Rodrigues RM; Mossman KL
Gene Ther; 2009 Sep; 16(9):1077-87. PubMed ID: 19474810
[TBL] [Abstract][Full Text] [Related]
33. IL-29 and IFN-α regulate the expression of MxA, 2',5'-OAS and PKR genes in association with the activation of Raf-MEK-ERK and PI3K-AKT signal pathways in HepG2.2.15 cells.
Chai Y; Huang HL; Hu DJ; Luo X; Tao QS; Zhang XL; Zhang SQ
Mol Biol Rep; 2011 Jan; 38(1):139-43. PubMed ID: 20309637
[TBL] [Abstract][Full Text] [Related]
34. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
35. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
Naik S; Nace R; Barber GN; Russell SJ
Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
[TBL] [Abstract][Full Text] [Related]
36. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.
Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):150-8. PubMed ID: 20959810
[TBL] [Abstract][Full Text] [Related]
37. Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells.
Wollmann G; Robek MD; van den Pol AN
J Virol; 2007 Feb; 81(3):1479-91. PubMed ID: 17108037
[TBL] [Abstract][Full Text] [Related]
38. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
Shinozaki K; Ebert O; Suriawinata A; Thung SN; Woo SL
J Virol; 2005 Nov; 79(21):13705-13. PubMed ID: 16227290
[TBL] [Abstract][Full Text] [Related]
40. VSV-tumor selective replication and protein translation.
Barber GN
Oncogene; 2005 Nov; 24(52):7710-9. PubMed ID: 16299531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]